Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1073 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 44, which is 17 points higher than the healthcare sector average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 30.53% over the past year, overperforming other healthcare stocks by 54 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 48.66% from Bioventus's current stock price of $10.09.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #2 top healthcare stock out of 1073 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: B.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 34, which is 7 points higher than the healthcare sector average of 27. It passed 11 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 68.73% over the past year, overperforming other healthcare stocks by 92 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $16.00, an upside of 27.8% from Amneal Pharmaceuticals's current stock price of $12.52.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Infusystem Holdings (NYSEMKT:INFU) is the #3 top healthcare stock out of 1073 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 42, which is 15 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has strong fundamentals. Infusystem Holdings has seen its stock return 106.8% over the past year, overperforming other healthcare stocks by 130 percentage points.

Infusystem Holdings has an average 1 year price target of $15.00, an upside of 45.07% from Infusystem Holdings's current stock price of $10.34.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 73 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

So Young International (NASDAQ:SY) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.41%.

So Young International's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 23.01%, which is 21 percentage points higher than the healthcare sector average of 2.41%.

Dominari Holdings's dividend payout ratio of -42.4% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 13.13%, which is 11 percentage points higher than the healthcare sector average of 2.41%.

Siga Technologies's dividend payout ratio of 181.8% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.19% in the last day, and down -3.18% over the last week. Sonoma Pharmaceuticals was the among the top losers in the healthcare sector, dropping -36.67% yesterday.

Sonoma Pharmaceuticals shares are trading lower after the company priced a $4 million public offering.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 70 points higher than the healthcare sector average of 16. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -21.53% in the past year. It has overperformed other stocks in the healthcare sector by 2 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 70 points higher than the healthcare sector average of 16. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 347.1% in the past year. It has overperformed other stocks in the healthcare sector by 371 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 4.66% in the past year. It has overperformed other stocks in the healthcare sector by 28 percentage points.

58.81% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 39.67% over the next year.

5.3% of healthcare stocks have a Zen Rating of A (Strong Buy), 11.96% of healthcare stocks are rated B (Buy), 50.68% are rated C (Hold), 24.41% are rated D (Sell), and 7.64% are rated F (Strong Sell).